LUPIN LTD

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai. Lupin develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.

Business segments

• Pharmaceuticals-99.54%
• Others-0.5%

Shareholding Pattern

-PUBLIC GROUP

-PROMOTER GROUP

Financial Summary

Synopsis of Financials

• Revenues in Q4 grew by 13% YoY, driven by major regions like U.S., India, EMEA, and APAC.
• Gross margins and operating margins improved in Q4 due to better business and product mix.
• EBITDA margins improved quarter over quarter despite higher R&D investments.
• U.S. business continued strong performance with $200 million plus revenues.
• New products like Tiotropium and generic Prolensa helped offset seasonal product decline.
• India business grew by 8.3% YoY in Q4 and 9.6% for FY24.
• EMEA and APAC regions recorded strong double-digit growth.
• Acquired two established brands from Sanofi for Europe and Canada.
• Closed Medisol transaction, expanding position in complex generics.
• R&D focus on complex products like inhalation and complex injectables.
• Compliance efforts ongoing with positive outcomes from recent inspections.

Final Outlook

Lupin’s future forecast suggests a potential upside, with analysts estimating a price target around 2,289.82 INR, ranging from a minimum of 1,834.00 INR to a maximum of 2,800.00 INR.

Here’s a more detailed breakdown:

• Price Target: TradingView analysts predict a price target of 2,289.82 INR for Lupin Ltd.
• Maximum and Minimum Estimates: The maximum estimate is 2,800.00 INR, while the minimum estimate is 1,834.00 INR.
• Revenue: In the next quarter, Lupin’s revenue is expected to reach 55.21 billion INR.
• Earnings Per Share (EPS): The EPS for the last quarter was 19.00 INR, despite an estimation of 17.94 INR. The next quarter’s EPS is expected to reach 16.65 INR.
• Analysts’ Opinions:analysts have a consensus estimate of 2329.44, representing a 14.49% upside from the last price of 2034.65.
• Lupin’s Financial Performance: Lupin has demonstrated robust financial performance in FY24, with total revenue surpassing INR 200 Bn, and EBITDA percentage growing sequentially every quarter.
• Stock Returns: The stock gave a 3-year return of 165.85% as compared to Nifty 100 which gave a return of 31.16%.
• Earnings Report: Lupin is going to release its next earnings report on May 13, 2025.
• Market Capitalization: Today, Lupin LTD has a market capitalization of 909.00 billion, which has increased by 0.75% over the last week.
• Volatility: Lupin stock is 2.59% volatile and has a beta coefficient of 0.77.
• Technical Analysis: Immediate support is at 1,910.53, and immediate resistance is at 2,053.23.
• Future Growth: The company’s pipeline, particularly in complex generics, injectables, and biosimilars, is expected to contribute majorly to future growth.

I would give buy recommendation for this stock.